Summit Therapeutics Inc. — Director's Dealing 2020

Nov 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-11-22

Reporting Person: Zanganeh Maky (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-22	Stock Option (right to buy)	$4.40	A	2400000	Acquired	2030-11-22	Common Stock (2400000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2254242	Indirect
Common Stock	2104541	Indirect

Footnotes

F1: The option was granted on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 22, 2021, subject to the satisfaction of certain performance targets.